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Introduction: Sepsis, a leading cause of death in critically ill patients, is the result of complex interactions between
the infecting microorganisms and the host responses that influence clinical outcomes. We evaluated the prognostic
value of presepsin (sCD14-ST), a novel biomarker of bacterial infection, and compared it with procalcitonin (PCT).
Methods: This is a retrospective, case–control study of a multicenter, randomized clinical trial enrolling patients
with severe sepsis or septic shock in ICUs in Italy. We selected 50 survivors and 50 non-survivors at ICU discharge,
matched for age, sex and time from sepsis diagnosis to enrollment. Plasma samples were collected 1, 2 and 7 days
after enrollment to assay presepsin and PCT. Outcome was assessed 28 and 90 days after enrollment.
Results: Early presepsin (day 1) was higher in decedents (2,269 pg/ml, median (Q1 to Q3), 1,171 to
4,300 pg/ml) than in survivors (1,184 pg/ml (median, 875 to 2,113); P = 0.002), whereas PCT was not different
(18.5 μg/L (median 3.4 to 45.2) and 10.8 μg/L (2.7 to 41.9); P = 0.31). The evolution of presepsin levels over time
was significantly different in survivors compared to decedents (P for time-survival interaction = 0.03), whereas PCT
decreased similarly in the two groups (P = 0.13). Presepsin was the only variable independently associated with ICU
and 28-day mortality in Cox models adjusted for clinical characteristics. It showed better prognostic accuracy than
PCT in the range of Sequential Organ Failure Assessment score (area under the curve (AUC) from 0.64 to 0.75 vs.
AUC 0.53 to 0.65).
Conclusions: In this multicenter clinical trial, we provide the first evidence that presepsin measurements may have
useful prognostic information for patients with severe sepsis or septic shock. These preliminary findings suggest
that presepsin may be of clinical importance for early risk stratification.Introduction
Sepsis is the leading cause of death in critically ill pa-
tients and requires early goal-directed management to
reduce its high burden of mortality and morbidity [1].
During sepsis, the combination of severe infection and
the subsequent nonlocalized inflammatory and immune-
mediated systemic responses may result in a clinical* Correspondence: serge.masson@marionegri.it
†Equal contributors
1IRCCS - Istituto di Ricerche Farmacologiche “Mario Negri”, via Giuseppe La
Masa 19, 20156 Milan, Italy
Full list of author information is available at the end of the article
© 2014 Masson et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcondition with lethality as high as 40% [2]. Despite ef-
forts to improve early recognition and clinical treatment,
sepsis often evolves to septic shock (that is, reduced tis-
sue perfusion despite fluid therapy and vasoactive drugs)
and multiorgan failure, which are the most frequent
causes of death in the septic patient. The host’s innate
and adaptive immune responses are fundamental in
defense against the infecting microorganisms, but they
also contribute to the amplification of proinflammatory
mechanisms, coagulation imbalance and endothelial dys-
function that participate in organ injury [3].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapies, so, in principle, it could be improved by indi-
vidualized circulating biomarkers for early risk stratifica-
tion. Circulating biomarkers may help in making the
diagnosis and guiding antimicrobial therapy for patients
with sepsis [4,5], but few have proved to be useful for in-
dividual prognostic stratification. Presepsin (sCD14-ST)
is a soluble N-terminal fragment of the cluster of differ-
entiation (CD) marker protein CD14, which is released
into the circulation during monocyte activation upon
the recognition of lipopolysaccharide (LPS) from infec-
tious agents [6]. It shows promise for diagnostic pur-
poses [7] and powerful prognostic information in septic
patients as early as the time of admission [8]. To date,
no multicenter study has been conducted to evaluate the
prognostic value of presepsin during severe sepsis. We
therefore set out to examine the relationships between
early plasma presepsin concentration and mortality in
patients with severe sepsis and septic shock and com-
pare its prognostic performance with that of procalcito-
nin (PCT).
Materials and methods
Study design
This retrospective case–control study was conducted with
data from the multicenter, randomized Albumin Italian
Outcome Sepsis (ALBIOS) trial, which enrolled patients
with severe sepsis or septic shock from 100 ICUs in Italy
(Clinicaltrials.gov Identifier: NCT00707122). The primary
aim of the trial was to verify whether volume replacement
with albumin and the maintenance of serum albumin
levels within the physiologic range during the first 28 days
(or until ICU discharge, whichever came first) improved
28-day and 90-day survival as compared to crystalloids.
Both arms of the study were carried out in accordance
with the Surviving Sepsis Campaign guidelines for early
goal-directed therapy and the treatment of patients with
severe sepsis [1,9].
We selected 50 survivors and 50 nonsurvivors at the
time of ICU discharge (21 ± 18 days). The cohorts were
matched for age, sex, source center and time of enroll-
ment after confirmation of the inclusion criteria (within
6 hours and between 6 and 24 hours), which were at least
one focus of infection (known or suspected), two or more
signs of systemic inflammatory reaction syndrome (core
temperature >38°C or <36°C; heart rate >90 beats/min; re-
spiratory rate >20 breaths/min or arterial partial pressure
of carbon dioxide <32 mmHg or requirement for mechan-
ical ventilation for an acute pathological process; white
blood cell count >12,000/μl or <4,000/μl or more than
10% immature neutrophils) and at least one severe, acute
sepsis-related organ dysfunction assessed on the basis of
the Sequential Organ Failure Assessment (SOFA) score
[10]. Exclusion criteria were age younger than 18 years,terminal state, a known adverse reaction to albumin, a
proved or suspected and clinically active brain injury, con-
gestive heart failure (New York Heart Association class III
or IV), a pathological condition in which albumin could be
clinically indicated (such as cirrhosis with ascites, intestinal
malabsorption syndrome, nephrotic syndrome or burns),
more than 24 hours elapsed since the presence of inclusion
criteria, patient’s religious objection to the administration of
human blood products and inclusion in other experimental
studies. Assignment to the randomization arm was not
known when patients were selected for the present case-
control study.
Clinical data on hemodynamic parameters, vasoactive
drug administration, blood gas analysis, ventilatory sta-
tus, fluid balance, antibiotic therapy and standard la-
boratory tests were obtained daily from the day of study
enrollment to day 28 (or until ICU discharge, whichever
came first). The Simplified Acute Physiology Score II
(SAPS II) was recorded within the first 24 hours after
enrollment, and the SOFA score was calculated daily.
For consistency between the indications provided by the
current guidelines for the management of severe sepsis
and septic shock [1] and for the calculation of the SOFA
score [10], the cardiovascular SOFA subscore was modi-
fied by lowering the mean arterial pressure limit to
65 mmHg for point 1. Moreover, the aggregate SOFA
score did not include neurological function, as cerebral
failure was not assessed during the study [11-13]. Data
on the initial site of infection and the infecting microor-
ganisms (based on infection site and blood culture) were
collected periodically. Septic shock at the time of
randomization was defined as a cardiovascular compo-
nent of the SOFA score of 1, 3 or 4 [11].
A complete list of centers and investigators participating
in the ALBIOS substudy on biomarkers is presented in
Additional file 1. This study was compliant with the 1975
Declaration of Helsinki as revised in 2008 and was
approved first by the Institutional Review Board of the
Fondazione IRCCS Ca' Granda - Ospedale Maggiore
Policlinico, Milan, Italy (coordinating center), and subse-
quently by the appropriate institutional review boards of
all the other participating centers (see Additional file 2).
Written informed consent or deferred consent was ob-
tained from all participants.
Sample collection and circulating biomarker
measurement
Ethylenediaminetetraacetic acid plasma samples were
serially collected 1, 2 and 7 days after enrollment (or at
ICU discharge, whichever came first), shipped on dry ice
to a central repository and stored at −70°C until assayed.
A central laboratory whose technicians were blinded to
patients’ characteristics measured presepsin (chemilu-
minescent enzyme immunoassay, PATHFAST Presepsin,
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R.A.H.M.S Cobas® PCT, Roche Diagnostics). For impre-
cision determination, four plasma samples were assayed
in duplicate on 20 nonconsecutive days. The PATHFAST
Presepsin assay revealed intra-assay and interassay coef-
ficients of variation (CVs) of 4.4% at 445 pg/ml. At
4,901 pg/ml, intra- and interassay CVs of 3.2% and 3.9%
were obtained, respectively. The limit of detection was
20 pg/ml. The Elecsys BRAHMS Cobas® PCT assay
yielded a limit of detection of 0.02 μg/L. The intra-
assay and interassay CVs were 9.9% and 16.3% at a
PCT concentration of 0.06 μg/L and 2.1% and 4.2% at
41.2 μg/L, respectively. Reference values (95th percentile)
measured in a control group of 110 healthy volunteers
were 320 pg/ml for presepsin (upper limit of normal) and
0.046 μg/L for PCT.Outcomes and statistical analysis
The primary outcome measure of the ALBIOS trial was
death recorded 28 and 90 days after enrollment. We also
evaluated the association between circulating biomarkers
and survival at ICU discharge. Categorical variables are
presented as proportions and continuous variables as
means (±SD) or medians (Q1 to Q3). Differences in clin-
ical characteristics according to survival status were ana-
lyzed using the χ2 test or Fisher’s exact test for
categorical variables. Continuous variables were com-
pared by performing a two-sample t-test or the nonpara-
metric Mann–Whitney U test for non-normally
distributed data. Changes of biomarker concentrations
over time in survivors and decedents were compared
using two-way analysis of variance for repeated measure-
ments on log-transformed data when appropriate. The
comparison of presepsin and PCT concentrations at 1, 2
and 7 days between decedents and survivors at ICU dis-
charge was performed using the Mann–Whitney U test
in both the overall study population and the subgroup of
patients with septic shock.
The relation between circulating biomarker concentra-
tions, entered as log-transformed continuous variables,
and mortality was first assessed with univariate Cox pro-
portional hazards models, and these data are presented
as hazard ratios (HRs) and 95% confidence intervals
(CIs) for a 1-unit increase on a logarithmic scale. Cumu-
lative sums of martingale-based residuals, plots and test-
ing were used to evaluate whether an independent
covariate could be entered directly into the model or if a
transformation was necessary. The effect of the absence
of the time dependence on the ability to predict out-
comes was confirmed by using the calculation method
proposed by Lin and colleagues [15], derived from the
same analysis of cumulative sums of martingale-based
residuals.Cox multivariate models were used to establish the in-
dependent prognostic value of circulating biomarkers
after adjustment for a set of clinically relevant variables
set a priori: SAPS II score; SOFA score and serum lac-
tate concentration, both measured on day 1; mean arter-
ial pressure and central venous oxygen saturation, both
measured at 6 hours after enrollment; and randomized
treatment (albumin vs. crystalloids). All of these covari-
ates were directly included in the model. The prognostic
discrimination of each biomarker and two clinical risk
scores (SOFA and SAPS II scores) was established on
the basis of the area under the receiver operating charac-
teristic (ROC) curve, which is equivalent to the C-index.
The optimal cutoff was chosen as the highest product of
sensitivity and specificity. Statistical analysis was done
using SAS version 9.2 software (SAS Institute, Cary, NC,
USA). A two-sided P value <0.05 was deemed to be
statistically significant.
Results
Presepsin concentration and baseline clinical
characteristics
Additional file 3 gives the selected clinical characteristics
of patients at the time of study enrollment according to
median levels of presepsin assessed on day 1 (1,494 pg/ml).
Higher levels of presepsin were significantly associated
with worse SOFA scores and reduced diuresis.
Time course of presepsin levels during the study period
Baseline clinical characteristics and circulating biomarker
concentrations measured at day 1 in survivors and non-
survivors at ICU discharge are presented in Table 1. The
only significant difference between the two groups was a
higher concentration of presepsin in nonsurvivors (P =
0.0015). The main clinical characteristics, risk scores
(SOFA score at enrollment and SAPS II score), as well as
PCT levels, were not significantly different.
The evolution of presepsin levels over time in survivors
was significantly different from that in nonsurvivors
(Figure 1) (P value for time–survival interaction = 0.03). At
all the three time points, presepsin levels were significantly
higher in the decedents than in the survivors (P < 0.005).
There was no significant difference in presepsin concentra-
tions measured on day 2 or day 7 compared to that on day
1 in both nonsurvivors and survivors. Conversely, PCT
levels fell rapidly and similarly in survivors and nonsurvi-
vors (Figure 1), and concentrations were significantly differ-
ent between the two groups only on day 7 (P = 0.01). PCT
levels measured on day 2 or day 7 were significantly lower
than those on day 1 (P < 0.0001 for survivors and P < 0.001
for nonsurvivors). The interaction between 7-day time
course and survival was significant for SOFA score (P =
0.008), but not for serum lactate concentration (P = 0.08) or
mixed venous oxygen saturation (SvO2) (P = 0.49).
Table 1 Baseline clinical characteristics and biomarkers in survivors and nonsurvivors at ICU dischargea
Characteristics Survivors (n = 50) Decedents (n = 50) P
Age (years) 71.6 ± 10.8 71.3 ± 13.6 0.63
Females, n (%) 23 (46) 23 (46) 1.00
BMI (kg/m2) 25.5 ± 4.9 28.4 ± 7.6 0.09
Randomized to albumin, n (%) 27 (54) 27 (54) 1.00
Source of severe sepsis, n (%)
Lungs 19 (38) 19 (38) 1.00
Abdomen 26 (52) 20 (40) 0.23
Urinary tract 8 (16) 10 (20) 0.60
Other 7 (14) 10 (20) 0.42
SAPS II score 50 ± 14 51 ± 12 0.75
SOFA score 8 (6 to 10) 9 (7 to 11) 0.10
Reason for ICU admission, n (%)
Medical 25 (50) 28 (56) 0.55
Emergency surgery 23 (46) 17 (34) 0.22
Elective surgery 2 (4) 5 (10) 0.44
Shock, n (%) 40 (80) 34 (68) 0.17
Mechanical ventilation, n (%) 44 (88) 45 (90) 0.75
Vasoactive drugs, n (%) 37 (74) 36 (72) 0.82
Heart rate (beats/min) 102 ± 27 103 ± 21 0.91
Mean arterial pressure (mmHg) 73 ± 16 73 ± 14 0.78
Central venous pressure (mmHg) 8.0 (6.0 to 13.7) 9.9 (7.3 to 12.5) 0.54
Central venous oxygen saturation (%) 75 (66 to 81) 73 (66 to 80) 0.53
Urine output (ml/h) 40 (16 to 100) 50 (20 to 90) 0.94
Serum lactate (mmol/L) 2.6 (1.6 to 4.2) 2.5 (1.8 to 4.2) 0.67
Plasma presepsin on day 1 (pg/ml) 1,184 (875 to 2,113) 2,269 (1,171 to 4,300) 0.0015
Plasma procalcitonin on day 1 (μg/L) 10.8 (2.7 to 41.9) 18.5 (3.4 to 45.2) 0.31
aBMI, Body mass index; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment. Continuous variables are presented as mean ± SD
or median and interquartile range when not normally distributed. Categorical variables are presented as number (%).
Figure 1 Time course of plasma concentrations of presepsin and procalcitonin during ICU stay by survival status. Plasma concentrations
of presepsin and procalcitonin 1, 2 and 7 days after enrollment in decedents (n = 50, black) and survivors (n = 50, gray) at ICU discharge. Data are
shown as median and interquartile range. Two-way ANOVA for repeated measurements was done on log-transformed biomarker concentrations.
**P < 0.005, *P = 0.01 by Mann–Whitney U test.
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tween patients with severe sepsis and those with septic
shock at the time of study enrollment, both on day 1
(1,571 pg/ml (793 to 2,440) (n = 26) vs. 1,485 pg/ml (960
to 3,501) (n = 74); P = 0.51) and at subsequent times
(data not shown). The same was true for SOFA score
and PCT (data not shown).
In the 74 patients with septic shock, presepsin was signifi-
cantly higher in decedents than in survivors, both at base-
line (2,590 pg/ml (1,631 to 4,310) vs. 1,170 pg/ml (890 to
1,799); P = 0.0007) (Figure 2) and on the following days
(P < 0.001). In contrast, early PCT levels (days 1 and 2) were
not different between the two groups with septic shock.
Presepsin levels did not differ significantly in relation to
the type of infection by either infection sites or blood cul-
tures (bacterial, fungal, mixed or undetermined) or by the
type of bacterial infection (purely Gram-negative, purely
Gram-positive, mixed or undetermined; data not shown).
Patients were stratified according to the time from ful-
fillment of inclusion criteria and study enrollment
(within 6 hours or between 6 and 24 hours). In patients
with early enrollment (within 6 hours), plasma concen-
trations of presepsin on day 1 were not significantly dif-
ferent between decedents (2,138 pg/ml (1,062 to 3,101);
n = 24) and survivors at ICU discharge (1,335 pg/ml
(879 to 2,856) (n = 25); P = 0.17). The same was true for
PCT (23.2 μg/L (3.3 to 64.1) vs. 10.9 μg/L (2.8 to 30.8);
P = 0.20). However, the plasma concentration of presep-
sin on day 1 was significantly higher in decedents ran-
domized between 6 and 24 hours after the onset of
inclusion criteria (2,621 pg/ml (1,223 to 4,959); n = 26)
than in the survivors at ICU discharge (1,044 pg/ml (875
to 1,331) (n = 25); P = 0.003), whereas PCT did not differ
(16.2 μg/L (3.4 to 40.6) vs. 7.1 μg/L (2.7 to 41.8);
P = 0.88).Figure 2 Time course of plasma concentrations of presepsin and proc
survival status. Plasma concentrations of presepsin and procalcitonin 1, 2
(n = 40, gray) with septic shock at ICU discharge. Data are shown as media
was done on log-transformed biomarker concentrations. **P < 0.001, *P = 0Plasma presepsin concentration in relation to mortality
The prognostic value of presepsin was evaluated at ICU
discharge and during follow-up period on days 28 and
90 after study enrollment according to prespecified study
endpoints. In univariate Cox proportional hazards
models (Table 2), presepsin on day 1 was associated with
mortality at ICU discharge (HR = 1.65 (95% CI = 1.22 to
2.24) for each 1 unit increase in log-transformed con-
centration; P = 0.0012), at 28 days (HR = 1.73 (95% CI =
1.32 to 2.27); P < 0.001) and at 90 days (HR = 1.50 (95%
CI = 1.18 to 1.91); P = 0.001). The corresponding HRs
and 95% CIs for PCT were 1.01 (95% CI =0.87 to 1.18;
P =0.88), 1.07 (95% CI = 0.92 to 1.25; P =0.40), and 1.03
(95% CI =0.91 to 1.18; P =0.63). After adjustment for
clinically relevant variables, including SAPS II score, SvO2
level and mean arterial pressure 6 hours after study enroll-
ment, as well as SOFA score and serum lactate level on
day 1, presepsin on day 1 remained independently related
to outcome at ICU discharge (HR = 1.48 (95% CI = 1.04
to 2.11; P = 0.03) and after 28 days (HR = 1.54 (95%
CI = 1.12 to 2.12); P = 0.01) (Table 2), but not after 90 days
(HR = 1.29 (95% CI = 0.96 to 1.72); P = 0.09).
Presepsin concentrations, but not PCT concentra-
tions, on days 2 and 7 were independently related to
mortality in the ICU, as well as on days 28 and 90
(Table 2). The SOFA score was the only clinical vari-
ables independently associated with mortality in the
multivariable models including PCT; when presepsin
was included in place of PCT in these models, the SOFA
score was no longer significantly associated with mor-
tality (data not shown).
Prognostic accuracy of presepsin
The prognostic accuracy of presepsin was evaluated on
the basis of ROC curves, yielding AUCs for ICU survivalalcitonin in patients with septic shock during ICU stay by
or 7 days after enrollment in decedents (n = 34, black) and survivors
n and interquartile range. Two-way ANOVA for repeated measurements
.007 by Mann–Whitney U test.
Table 2 Univariate and multivariate Cox models for mortalitya
Time Biomarker ICU mortality 28-day mortality 90-day mortality
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Day 1 Presepsin 1.65
(1.22 to 2.24)
0.001 1.51
(1.05 to 2.17)
0.03 1.73
(1.32 to 2.27)
<0.0001 1.55
(1.12 to 2.13)
0.008 1.50
(1.18 to 1.92)
0.001 1.28
(0.96 to 1.71)
0.09
Procalcitonin 1.01
(0.87 to 1.18)
0.88 0.89
(0.75 to 1.05)
0.15 1.07
(0.92 to 1.25)
0.40 0.97
(0.84 to 1.12)
0.68 1.03
(0.91 to 1.18)
0.63 0.94
(0.83 to 1.06)
0.32
Day 2 Presepsin 1.84
(1.33 to 2.54)
0.0002 1.83
(1.19 to 2.81)
0.006 2.02
(1.49 to 2.75)
<0.0001 1.93
(1.27 to 2.92)
0.002 1.73
(1.31 to 2.28)
0.0001 1.47
(1.02 to 2.12)
0.04
Procalcitonin 1.00
(0.86 to 1.16)
0.97 0.82
(0.68 to 0.98)
0.03 1.05
(0.90 to 1.23)
0.54 0.85
(0.70 to 1.02)
0.08 1.06
(0.92 to 1.21)
0.43 0.86
(0.73 to 1.02)
0.08
Day 7 Presepsin 1.77
(1.30 to 2.41)
0.0003 1.83
(1.22 to 2.74)
0.004 2.11
(1.55 to 2.89)
<0.0001 2.13
(1.41 to 3.21)
0.0003 1.84
(1.41 to 2.41)
<0.0001 1.75
(1.23 to 2.48)
0.002
Procalcitonin 1.12
(0.93 to 1.33)
0.23 0.97
(0.78 to 1.21)
0.78 1.29
(1.06 to 1.57)
0.01 1.11
(0.87 to 1.42)
0.39 1.25
(1.05 to 1.47)
0.01 1.08
(0.88 to 1.33)
0.46
aRisk is presented as hazard ratio and 95% confidence interval with an increment of 1 unit after logarithmic transformation of the biomarker concentration. The
following covariates, deemed important clinical variables, were considered in the multivariable models: Simplified Acute Physiology Score II score, Sequential
Organ Failure Assessment score, serum lactate concentration, mean arterial pressure, central venous oxygen saturation and randomized treatment (albumin
vs. crystalloids).
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(Table 3). The SOFA score had similar accuracy. Corre-
sponding values for PCT were 0.56, 0.55 and 0.64,
respectively.
Discussion
Severe sepsis is still a major challenge in critical care.
Over the past ten years, many efforts have improved sev-
eral aspects of its treatment and prognosis, such as
earlier identification of the potential infection, early
etiologic therapy and early implementation of adequate
supportive therapy while avoiding potential harmful ef-
fects [1,16]. Nonetheless, the early stratification of pa-
tients with severe sepsis and their prognosis, as well as
accurate monitoring of the effects of clinical treatment,
is still an unsolved issue. Clinical scores have been intro-
duced in clinical practice to partially satisfy this task,
such as the SOFA score [10] and the Acute Physiology
and Chronic Health Evaluation II score [17], but the
state of the art in diagnosing and monitoring severe sep-
sis on the basis of circulating biomarkers relies on PCT
at the onset and during the course of the disease [18].
Despite all the data available and widespread clinical im-
plementation, PCT has shown limited value for risk
stratification and prognostication.
The 55 kDa glycoprotein CD14 is expressed on the
membrane of monocytes and macrophages. It facilitates
the Toll-like receptor 4–specific inflammatory reaction
whereby soluble CD14 (sCD14) is released into the cir-
culation and serves as a mediator of the response to LPS
from infectious agents. Simultaneously, a 13 kDa frag-
ment of sCD14, named sCD14-ST or presepsin, is
formed [19]. Although its biological function remains
unclear, it appears to be released in the plasma as a con-
sequence of cellular phagocytosis after bacterial infection
and is therefore an indirect marker of sepsis [20]. It wasidentified less than one decade ago in patients with sepsis
and appears to be superior to other biomarkers (IL-6 and
PCT), as well as to infection site and blood culture, for
the diagnosis of severe sepsis of bacterial origin [7,20].
In our present multicenter, case–control study, we in-
vestigated the potential prognostic power of presepsin
during ICU stay in patients with severe sepsis. A recent
study of 106 patients presenting at the emergency de-
partments of two hospital centers with suspected sepsis
or septic shock showed that presepsin measured on the
first medical evaluation (but not successively) was asso-
ciated with 60-day mortality by univariate analysis [21].
In our study, presepsin levels on day 1 remained inde-
pendently associated with mortality at early stages (at
ICU discharge and after 28 days), even after correction
for the individual clinical variables considered to be the
most important parameters of the resuscitation phase
(mean arterial pressure, serum lactate level and central
venous oxygen saturation) [1,11]. The models were also
adjusted for widely used clinical scores of overall severity
(such as SAPS II score) [22] or multiorgan failure (such
as SOFA score) [10]. No independent association was
observed between any of these variables and mortality
when presepsin was included in the models. Taken to-
gether, these findings suggest that presepsin is a robust
circulating biomarker for early stratification of the sever-
ity of sepsis, as well as for patient prognosis. Although
there is contrasting evidence on the independent prog-
nostic value of PCT in septic patients [23,24], there is a
consensus that its main clinical use is to aid in the moni-
toring of antibiotic therapy. Sepsis is a complex syndrome
with an initial phase (usually the first 48 hours) in which
appropriate etiological therapy and adequate supportive
treatment must be established, followed by a second phase
when multiple organ failures may occur. Presepsin, being
superior as an early prognostic factor to clinical
Table 3 Prognostic accuracy of presepsin, procalcitonin and clinical risk scoresa
ICU survival 28-day survival 90-day survival
AUC
(95% CI)
Optimal
cutoff
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
LR
+
LR
−
AUC
(95% CI)
Optimal
cutoff
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
LR+ LR− AUC
(95% CI)
Optimal
cutoff
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
LR
+
LR
−
Presepsin
Day 1 0.69
(0.58 to 0.79)
1631 66.7 74.0 71 70 2.56 0.45 0.72
(0.61 to 0.82)
1631 67.4 70.9 64 74 2.32 0.46 0.66
(0.55 to 0.77)
1631 62.5 71.4 76 58 2.19 0.53
Day 2 0.70
(0.59 to 0.87)
1718 69.4 73.5 72 71 2.62 0.42 0.74
(0.64 to 0.85)
1718 74.4 72.7 68 78 2.73 0.35 0.68
(0.57 to 0.79)
1407 77.2 61.0 73 66 1.98 0.37
Day 7 0.74
(0.64 to 0.84)
1606 72.0 70.0 71 71 2.40 0.40 0.74
(0.64 to 0.84)
2028 63.6 76.8 68 73 2.74 0.47 0.70
(0.60 to 0.81)
1453 70.7 64.3 73 61 1.98 0.46
Procalcitonin
Day 1 0.56
(0.44 to 0.68)
14.27 60.4 58.0 58 60 1.44 0.68 0.55
(0.44 to 0.67)
14.27 60.5 56.4 52 65 1.39 0.70 0.53
(0.41 to 0.65)
14.27 57.1 57.1 64 50 1.33 0.75
Day 2 0.55
(0.44 to 0.67)
8.88 60.4 55.1 57 59 1.35 0.72 0.53
(0.41 to 0.65)
8.88 59.5 52.7 49 63 1.26 0.77 0.55
(0.43 to 0.67)
8.88 60.7 58.5 67 52 1.46 0.67
Day 7 0.64
(0.54 to 0.75)
1.51 56.0 74.0 68 63 2.15 0.59 0.65
(0.54 to 0.76)
1.47 61.4 73.2 64 71 2.29 0.53 0.63
(0.52 to 0.74)
1.47 55.2 76.2 76 55 2.32 0.59
SOFA score
Day 1 0.69
(0.59 to 0.80)
9 65.3 68.8 68 66 2.09 0.50 0.68
(0.58 to 0.79)
9 67.4 66.7 62 72 2.02 0.49 0.68
(0.57 to 0.79)
9 61.4 70.0 74 57 2.05 0.55
Day 2 0.67
(0.56 to 0.78)
8 73.9 54.2 61 68 1.61 0.48 0.72
(0.61 to 0.82)
9 70.0 64.8 60 74 1.99 0.46 0.64
(0.53 to 0.76)
8 70.4 55.0 68 58 1.56 0.54
Day 7 0.75
(0.65 to 0.85)
7 59.6 83.0 78 67 3.50 0.49 0.75
(0.65 to 0.85)
7 61.0 79.2 69 72 2.94 0.49 0.71
(0.60 to 0.81)
6 66.7 65.0 72 59 1.91 0.51
SAPS II
Day 1 0.51
(0.39 to 0.62)
49 56.0 48.0 52 52 1.08 0.92 0.63
(0.52 to 0.74)
51 61.4 60.7 55 67 1.56 0.64 0.58
(0.47 to 0.70)
49 60.3 54.8 65 50 1.33 0.72
a95% CI, 95% confidence interval; LR+, positive likelihood ratio; LR−, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; Simplified Acute Physiology Score II score, Sequential Organ
Failure Assessment score. The areas under the receiver operating characteristic curve (AUCs) are shown as means (95% confidence intervals).
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tics encompassing the complexity of the whole syndrome.
With regard to the time course of presepsin, we ob-
served a significant difference between survivors and non-
survivors. PCT decreased in both groups, as already
observed by others [25]. This suggests that presepsin may
also be used for monitoring the efficacy of the therapy
adopted—etiologic, supportive or both—as previously sug-
gested [6,20]. Although our study design did not allow us
to demonstrate any direct association between the treat-
ment applied and late levels of presepsin, we speculate
that the drop in presepsin levels in patients who survived
indicates a beneficial effect of the treatment by reducing
the activity of the bacterial infection or by controlling its
systemic reactivity. Because presepsin has previously been
identified as a promising biomarker for the diagnosis of
sepsis, superior even to conventional markers and blood
culture [6,7], it is conceivable that early assessment of cir-
culating presepsin might help in making early, correct
diagnoses, as well as in monitoring the appropriateness of
the therapy implemented.
When we compared presepsin levels to clinical scores,
the prognostic accuracy of presepsin level appeared to be
similar to that of the SOFA score for both early (ICU
discharge and after 28 days) and late mortality (90-day).
This seems reasonable because the SOFA score—the most
commonly used clinical score to assess the development
of organ failures—relies on the concept that the higher the
severity and number of organ failures during the course of
sepsis, the greater the likelihood of death [10]. It is tempt-
ing to speculate, too, that the greater the host’s biological
response to the microorganism (due either to its virulence
or to the immune reaction) and therefore, indirectly, the
higher the levels of plasma presepsin, the greater the se-
verity of sepsis, the risk of multiple organ dysfunction and
ultimately the risk of death.
Some limitations of the present study deserve consi-
deration. First, the relatively small sample size did not
allow in-depth analysis of the relationships between pre-
sepsin levels and disease characteristics (for example,
infecting organism, source of sepsis) or severity (for ex-
ample, physiological score, multiorgan failure) as well as
the therapy applied. Second, we conducted a retrospective
case–control study with inherent selection bias and thus
we might have overlooked some confounding factors. Al-
though we cannot exclude the possibility that selecting the
study population according to early ICU survival might
have partially affected our findings, the evaluation of out-
comes even after 28 and 90 days likely supported the
plausibility of our observations, which await further
validation. Third, although extensive daily monitoring
of circulating biomarkers is important during the early
management of sepsis [26], only three measurements
(on days 1, 2 and 7) were available.Conclusion
In this study, we show for the first time that presepsin is
an early marker of mortality with better prognostic per-
formance than PCT and that it may be proposed as an aid
in risk stratification strategies in the septic patient. These
preliminary findings provide a solid basis for future, more
extensive evaluation of presepsin as a biomarker for severe
sepsis. More insight is needed regarding the pathophysio-
logical conditions associated with presepsin release, both
in experimental models of sepsis and in well-characterized
patients. The added value of this biomarker for clinical
decision-making in terms of diagnosis, risk stratification
and therapy monitoring should also be delineated. The
clinical indications for presepsin should be confirmed and
validated in large-scale, independent cohorts of unselected
patients with severe sepsis or septic shock.
Key messages
 Circulating presepsin (sCD14-ST) levels have a
significantly different trajectory over the ICU stay in
decedents with severe sepsis and septic shock
compared to survivors.
 Presepsin is an early marker of mortality,
independently of clinical risk factors, with better
prognostic performance than PCT.
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